BOTHELL, Wash.--(BUSINESS WIRE)--March 10, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Daniel F. Hoth, M.D., a clinical and drug development veteran with more than 25 years of experience, has been appointed to the company’s Board of Directors.
